Literature DB >> 28903522

Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience.

Sherry Mathew1, Michelle L Kussin1, Dazhi Liu1, Melissa Pozotrigo1, Brian Seyboth1, Jennifer Thackray1, Shirley Qiong Yan1, Meier Hsu2, Nina Cohen1, Susan K Seo3.   

Abstract

Limited data on optimal posaconazole dosing strategies for pediatric patients exist. In this study, we found that the median initial dose in patients who achieved a posaconazole plasma concentration of 0.7 μg/mL was 22.8 mg/kg per day whereas the median initial dose in those who did not reach the target concentration was 15.8 mg/kg per day; this result suggests that higher initial doses might be warranted.
© The Author 2017. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  oncology; pediatrics; posaconazole

Mesh：

Substances：

Year:  2017        PMID： 28903522      PMCID： PMC5907872          DOI： 10.1093/jpids/pix058

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  8 in total

1.  Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.

Authors:  S H Jang; P M Colangelo; J V S Gobburu
Journal:  Clin Pharmacol Ther       Date:  2010-05-26       Impact factor: 6.875

2.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

3.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

4.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

5.  Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.

Authors:  Valeria A Bernardo; Shane J Cross; Kristine R Crews; Patricia M Flynn; James M Hoffman; Katherine M Knapp; Jennifer L Pauley; Alejandro R Molinelli; William L Greene
Journal:  Ann Pharmacother       Date:  2013-06-04       Impact factor: 3.154

6.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

7.  Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.

Authors:  Gopal Krishna; Monika Martinho; Pranatharthi Chandrasekar; Andrew J Ullmann; Hernando Patino
Journal:  Pharmacotherapy       Date:  2007-12       Impact factor: 4.705

8.  Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.

Authors:  Michaela Döring; Carsten Müller; Pascal-David Johann; Annika Erbacher; Astrid Kimmig; Carl-Philipp Schwarze; Peter Lang; Rupert Handgretinger; Ingo Müller
Journal:  BMC Infect Dis       Date:  2012-10-19       Impact factor: 3.090
  8 in total
  1 in total

1.  Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients.

Authors:  Mengmeng Jia; Qiwen Zhang; Zifei Qin; Dao Wang; Peng Liu; Jing Yang; Xiaojian Zhang
Journal:  Front Pharmacol       Date:  2022-04-19       Impact factor: 5.988
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.